The use of at-home remedies for many dermatologic issues is common, as some patients do not seek professional care either for lack of access, excessive cost of prescription medication, or desire for a more "natural" solution. As these over-the-counter compounds become more prevalent, it is important for dermatologists to be aware not only of the chemicals that they contain but also of their potential adverse effects. It is important to educate and warn patients that not only will these compounds probably not achieve the desired endpoint but they may lead to unwanted cosmetic results and even permanent scarring.
{"title":"Beware of Home Remedies for Mole Removal.","authors":"Casey L Ross, Nazanin Saedi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The use of at-home remedies for many dermatologic issues is common, as some patients do not seek professional care either for lack of access, excessive cost of prescription medication, or desire for a more \"natural\" solution. As these over-the-counter compounds become more prevalent, it is important for dermatologists to be aware not only of the chemicals that they contain but also of their potential adverse effects. It is important to educate and warn patients that not only will these compounds probably not achieve the desired endpoint but they may lead to unwanted cosmetic results and even permanent scarring.</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9808192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 30-year-old woman visited the dermatology and venereology clinic with red rashes on her cheeks with spreading wounds to the ears present for 6 months. Similar ailments were also found on the chest and upper arms accompanying black spots on both palms. Initially, red rashes appeared intermittently, observed around the eyes and cheeks, especially at sun exposure. Tenderness or pruritus was not present; however, the patient had joints ache, sore fingers, hair loss as well as frequent fever.
{"title":"Recalcitrant Cutaneous Lupus Erythematosus during COVID-19 Pandemic: A Case Report.","authors":"Muhlis Yunus, Andi Putri Dahliana, Wiwiek Habar, Faridha Ilyas, Jonathan Kurnia Wijaya","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 30-year-old woman visited the dermatology and venereology clinic with red rashes on her cheeks with spreading wounds to the ears present for 6 months. Similar ailments were also found on the chest and upper arms accompanying black spots on both palms. Initially, red rashes appeared intermittently, observed around the eyes and cheeks, especially at sun exposure. Tenderness or pruritus was not present; however, the patient had joints ache, sore fingers, hair loss as well as frequent fever.</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rubén Linares-Navarro, Gorka Ruiz-Carrillo Ramírez, Héctor Perandones-González, Manuel Ángel Rodríguez-Prieto
A 91-year-old man presented with pruriginous tense blisters and erosions on the upper and lower extremities (Figures 1A and 1B). Mucous membranes were unaffected and Nikolsky's sign was negative. These lesions appeared 48 hours after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine. The patient had received the first dose of the same vaccine 23 days prior to the onset of lesions. He did not suffer from any other post-vaccination adverse effects.
{"title":"Bullous Pemphigoid Developed after the COVID-19 Vaccine.","authors":"Rubén Linares-Navarro, Gorka Ruiz-Carrillo Ramírez, Héctor Perandones-González, Manuel Ángel Rodríguez-Prieto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 91-year-old man presented with pruriginous tense blisters and erosions on the upper and lower extremities (Figures 1A and 1B). Mucous membranes were unaffected and Nikolsky's sign was negative. These lesions appeared 48 hours after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine. The patient had received the first dose of the same vaccine 23 days prior to the onset of lesions. He did not suffer from any other post-vaccination adverse effects.</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aditya K Gupta, Tong Wang, Kimberly Vincent, William Abramovits
SOTYKTUTM (deucravacitinib) is a newly approved oral agent for managing moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is a highly selective allosteric tyrosine kinase 2 inhibitor targeting dysregulated cytokine responses in psoriasis patients. Its efficacy was demonstrated in two randomized, placebo- and active comparator-controlled phase 3 trials, where a significantly higher proportion of patients, up to 58.4% (194/332), achieved lessening of symptoms at week 16. The recommended dosing regimen of deucravacitinib is 6 mg once daily. More frequent adverse reactions occurring in the deucravacitinib-treated patients include upper respiratory infection (19.2% [161/840]), increase in blood creatine phosphokinase (2.7% [23/840]), herpes simplex infection (2.0% [17/840]), mouth ulcers (1.9% [16/840]), folliculitis (1.7% [14/840]), and acne (1.4% [12/840]). Continuance of treatment for up to week 52 did not increase the exposure-adjusted rates of adverse reactions. The selectivity and specificity of deucravacitinib treatment may improve its long-term safety profile, compared to other Janus kinase inhibitors.
{"title":"SOTYKTU<sup>TM</sup> (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis.","authors":"Aditya K Gupta, Tong Wang, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>SOTYKTU<sup>TM</sup> (deucravacitinib) is a newly approved oral agent for managing moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is a highly selective allosteric tyrosine kinase 2 inhibitor targeting dysregulated cytokine responses in psoriasis patients. Its efficacy was demonstrated in two randomized, placebo- and active comparator-controlled phase 3 trials, where a significantly higher proportion of patients, up to 58.4% (194/332), achieved lessening of symptoms at week 16. The recommended dosing regimen of deucravacitinib is 6 mg once daily. More frequent adverse reactions occurring in the deucravacitinib-treated patients include upper respiratory infection (19.2% [161/840]), increase in blood creatine phosphokinase (2.7% [23/840]), <i>herpes simplex</i> infection (2.0% [17/840]), mouth ulcers (1.9% [16/840]), folliculitis (1.7% [14/840]), and acne (1.4% [12/840]). Continuance of treatment for up to week 52 did not increase the exposure-adjusted rates of adverse reactions. The selectivity and specificity of deucravacitinib treatment may improve its long-term safety profile, compared to other Janus kinase inhibitors.</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"16th World Congress of the International Academy of Cosmetic Dermatology.","authors":"Vesna M Petronic-Rosic","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10532290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nardo Zaias, Sandra X Escovar, Natalie G Dou, Martin N Zaiac, Julia Escandon, Carlos Ricotti
{"title":"Normal Lipid Distribution of the Nail Plate.","authors":"Nardo Zaias, Sandra X Escovar, Natalie G Dou, Martin N Zaiac, Julia Escandon, Carlos Ricotti","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9472288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dessyslava G Nikolaeva, Ivan A Bogdanov, Miroslava I Kadurina, Nikolai K Tsankov
A 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of recent infections, inflammatory conditions, malignancies, or drugs administration.
{"title":"Erythema Nodosum Induced by the Pfizer- BioNTech Vaccine.","authors":"Dessyslava G Nikolaeva, Ivan A Bogdanov, Miroslava I Kadurina, Nikolai K Tsankov","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of recent infections, inflammatory conditions, malignancies, or drugs administration.</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号